Abstract
Nanotechnologies have already attracted over $3bn of global government funding as part of efforts to enhance a range of disciplines including pharmaceuticals, drug delivery and healthcare monitoring. Advances in nanomaterials, nanostructures and nanosystems are expected to drive the value of the global nanotehnology market to over a trillion dollars by 2015, but many companies are remaining cautious, preferring to monitor developments in academia prior to making substantial investments. Despite such trepidation, the pharma industry is beginning to adopt nanotools throughout the R&D process to facilitate the high throughput screening of drug repositories, the identification of new drug targets and biomarkers for preclinical and clinical studies and the development of diagnostics and imaging agents.
' Nanotechnology' is a new report published by Business Insights that provides a comprehensive review of nanotechnology and it' s role in the development of next-generation nanomedicines. The nanotools and detection systems currently driving nanotechnology are profiled and the applications of nanotechnologies within the R&D process are assessed. This report measures the impact of nanotechnologies currently being applied to target cancer, cardiovascular disease and CNS disorders and also explores the implementation strategies of leading pharmaceutical, healthcare and nanotechnology start-ups.
Use this new report to assess the future of nanotechnology within pharma R&D, identify the innovations driving growth within the market and examine the implementation strategies of leading companies.
Table of Contents
Executive summary
- Nanotechnology: driving change in pharmaceutical R&D
- Nanotechnology: drug research & development
- Nanotechnology: nanoformulations & nanocarriers
- Nanotechnology: diagnostics & imaging
- Nanotechnology: therapeutic applications
- Nanotechnology: regulations, patents and scientific publications
- Nanotechnology: challenges, opportunities & future applications
Chapter 1 Driving change in pharmaceutical R&D
- Summary
- Defining nanotechnology
- Nanotechnology funding
- Nanotechnology evolution
- Nanotechnology in the pharma industry
- Nanotechnology start-up companies
- Nanotechnology in academia
- Drivers of nanotechnology research
- Report Outline
Chapter 2 Drug research & development
- Summary
- Introduction
- Nanotechnology in drug discovery & development
- Nanotools for drug discovery & development
- Application of nanotools in drug discovery & development
- Nanoscaffolding
- Nanoarrays
- BioForce Nanosciences
- Nanogen
- Nanotubes & nanosensors
- Nano-Proprietary Inc
- Carbon Nanotechnologies Inc
- Nanowires & cantilevers
- Microfluidic lab-on-a-chip
- Caliper Life Sciences
- Nanofluidic lab-on-a-chip
- Quantum Dots
- Evident Technologies
- Biomarker Harvesting
- Instruments for nanodetection and analysis
- Atomic force microscopy
- Surface Plasmon Resonance
- Instruments for nanofabrication
- Dip Pen Nanolithography (DPN)
- Conclusions
Chapter 3 Nanoformulations & nanocarriers
- Summary
- Introduction
- Leading companies in nanoformulations
- Approved nanoformulations
- Dendrimers
- Liposomal formulations
- Pegylated liposomal formulations
- Nanocrystal formulations
- Nanoparticle formulations
- Developmental nanoformulations
- Protein-stabilized liposomal formulations
- Controlled-release liposomal formulations
- New controlled-release nanoparticle and nanosphere formulations
- Magnetic nanoparticle formulations
- Novel nanomaterials for drug delivery
- Nanobombs
- Nanoshells
- Nanotubes
- Conclusions
Chapter 4 Diagnostics & imaging
- Summary
- Introduction
- Nanoarrays
- Cystalline nanoarrays
- Nanodevices
- Magnetic nanoparticles, nanocapsules and nanocells
- Nanoparticle barcodes
- Multifunctional nanoparticles and nanocells
- Gold nanoparticles
- Fluorescent nanoparticles
- Fluorescent nanocrystals
- Nanoscale contrast agents
- Multiplex imaging agents/therapeutics
- Conclusions
Chapter 5 Therapeutic applications
- Summary
- Introduction
- Nanotechnology in cancer
- Research
- In Vivo imaging
- Molecular imaging & diagnostics
- Drug delivery
- Cancer conclusions
- Nanotechnology in cardiovascular disease
- Therapeutic research
- Molecular imaging & diagnostics
- Tissue engineering & regenerative medicines
- Medical devices
- Drug delivery
- Cardiovascular conclusions
- Nanotechnology in CNS
- Research & development
- Diagnostics & imaging
- Drug delivery
- Neurodevices and nanowires
- CNS conclusions
- Overall conclusions
Chapter 6 Regulations, patents and scientific publications
- Summary
- Nanotechnology Guidelines
- Patentability and publications
- Nanotechnology patents
- Nanotechnology-based publications
- Conclusions
Chapter 7 Challenges, opportunities and future applications
- Summary
- Introduction
- Challenges in adopting nanotechnology
- Regulations
- Legal, political and ethical issues
- Public perception of nanotechnology
- Multidisciplinary infrastructure
- Intellectual property
- Commerciality of existing nanotechnology and medicines
- Opportunities for adopting nanotechnology
- Product repositioning
- New imaging agents for early disease detection
- Point-of-care diagnostics
- Personalized medicines
- Implementing nanotechnology in the pharma industry
- Competitive strategies
- AstraZeneca
- Bristol-Myers Squibb
- GlaxoSmithKline
- Novartis
- Roche
- Pfizer
- Elan Corporation
- Genentech
- GE Healthcare
- Siemens Medical Solutions
- Abraxis BioSciences
- pSividia Limited
- StarPharma Holdings Ltd
- Alliances & licensing
- Future impact of nanotechnology on drug discovery & development
Chapter 8 Appendix
- Glossary
- Bibliography
- Index
- Endnotes
List of Figures
- Figure 1.1: Nanometer scale
- Figure 1.2: Top-down and bottom-up nanotechnology approach
- Figure 1.3: Applications of nanotechnology
- Figure 1.4: Global nanotechnology funding, 2003
- Figure 1.5: Global nanotechnology market by 2015
- Figure 1.6: Evolution of nanotechnology 2000-2020
- Figure 1.7: Evolution of the nanotechnology market
- Figure 1.8: Nanotechnology applications in the pharma industry
- Figure 2.9: Nanotechnology innovating the R&D process
- Figure 2.10: Applications of nanotechnologies in drug discovery & development
- Figure 2.11: TEM of native collagen fibers and nanoscaffolding
- Figure 2.12: Array of probes on nanoarray
- Figure 2.13: Bead Nanoarrays from NanoVic
- Figure 2.14: NanoChip® 400 System
- Figure 2.15: Nanosensors for analyte detection
- Figure 2.16: Nanowires and cantilevers for nanodetection and multiplexing
- Figure 2.17: Scanning electron microscope image of a five-nozzle M3 emitter
- Figure 2.18: Evolution of microfluidics and nanofluidics in the pharma industry
- Figure 2.19: Nanoparticle bioconjugate harvesting platform
- Figure 2.20: Schematic of ATM technology
- Figure 2.21: AFM images measuring real-time cell activity
- Figure 2.22: Schematic of SPR technology
- Figure 2.23: Schematic of DPN technology and its applications
- Figure 3.24: Nanoformulations driving drug delivery
- Figure 3.25: Dendrimer structure
- Figure 3.26: Dendrimer delivery platform
- Figure 3.27: DauxoXome® liposomal formulation
- Figure 3.28: Doxil® liposomal formulation versus non-liposomal formulation
- Figure 3.29: Enhanced bioavailability and absorption rate with Nanocrystals technology
- Figure 3.30: Abraxane nab technology - Photosphere
- Figure 3.31: Micellar nanoparticles (MNP)
- Figure 3.32: Controlled-release liposomal formulations
- Figure 3.33: Fullerene structures A) C-60 and B) C-70
- Figure 3.34: AuroLase™ treated mice versus sham treatment
- Figure 3.35: Carbon nanotubes
- Figure 4.36: Nanotechnologies advancing diagnostics and imaging
- Figure 4.37: ViriChip™ Virus Detection Platform
- Figure 4.38: S-layer technology platform
- Figure 4.39: Sensation™ Virus Detection Platform
- Figure 4.40: BioNanoChannel ™ Bacterial Detection Platform
- Figure 4.41: Biobarcode assays for the detection of PSA
- Figure 4.42: Biosensor biobarcode
- Figure 4.43: Oxonica' s Nanoplex™ biotag and POC diagnostic
- Figure 4.44: AuroVist™ microCT image
- Figure 4.45: NanoStrings™ Nanoparticle Barcoding
- Figure 4.46: Schematic of fluorescent A) lanthanide structure and B) lanthanide nanoparticles
- Figure 4.47: QDot Nanocrystal Structure
- Figure 4.48: TriLite™ Emission Spectra
- Figure 4.49: Viral Capsids as imaging carriers
- Figure 4.50: Multifunctional nanocarriers for detection, diagnosis and treatment
- Figure 4.51: Nanotechnology improving molecular detection and diagnosis of cancer
- Figure 5.52: Application of nanotechnology in cancer, cardiovascular and CNS disorders
- Figure 5.53: Cyberkinetic' s brain gate
- Figure 6.54: Federal regulators addressing different aspects of nanotechnology
- Figure 6.55: Japanese Governmental System for Science & Technology
- Figure 6.56: Worldwide nanopatents 1995-2003
- Figure 6.57: Worldwide nanopatents by region of applicant and inventor
- Figure 6.58: Worldwide nanoscientific publications per world region
- Figure 6.59: Worldwide nanoscientific publications per country and subfield 1999-2004
- Figure 7.60: Future impact of nanotools on pharmaceuticals and healthcare
- Figure 7.61: Health care trends to 2020 - GlaxoSmithKline
List of Tables
- Table 1.1: Leading nanotechnology start-up companies
- Table 1.2: Leading nanotechnology institutes, forums and networking organizations
- Table 2.3: Key attributes of PuraMatrix versus other ECMs
- Table 2.4: Leading Lab-on-Chip (LOC) and microfluidic manufacturers
- Table 2.5: Leading manufacturers of QDots
- Table 2.6: Advantages of DPN versus other top-down and bottom-up fabrication technologies
- Table 3.7: Approved nanoformulations
- Table 3.8: Leading nanoformulation companies
- Table 4.9: Leading diagnostics and imaging companies evaluating nanotechnology
- Table 5.10: Nano-enabled delivery system for cancer therapeutics
- Table 5.11: Approved & developmental cancer nanomedicines
- Table 5.12: Nanotechnology application in cardiovascular devices
- Table 5.13: Nano-enabled delivery system under evaluation for cardiovascular therapies
- Table 5.14: Nano-enabled delivery system under evaluation for CNS therapies
- Table 7.15: Recent alliances and licensing deals in nanotechnology
